ArticleBMC pregnancy and childbirth2026
Antihypertensive drug use for hypertensive disorders of pregnancy in hospitals across nine Chinese cities: a real-world data study.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo investigate the prescribing patterns of antihypertensive drugs for hypertensive disorders of pregnancy (HDP) in hospitals across nine chinese cities from 2019 to 2024.
methodsMedication use data for HDP patients were extracted from the database of the Hospital Pharmacy Committee of the Chinese Pharmaceutical Association, covering hospitals in nine major cities across China. The analysis included indicators such as total number of prescriptions, patient age, regional, average prescription cost, defined daily doses (DDDs), defined daily cost (DDC), and B/A ratio (ranking ratio). Furthermore, patterns of combination therapy and prescription rationality were assessed.
resultsBetween 2019 and 2024, HDP patients were concentrated in the age of 30-34 years and in the North China region. Among outpatients, the top three antihypertensive drugs were oral labetalol (75.90%), oral nifedipine (17.42%), and oral methyldopa (3.36%). Among inpatients, the top three antihypertensive drugs were oral nifedipine (42.69%), oral labetalol (38.86%), and nicardipine for injection (5.84%). In outpatient, monotherapy accounted for 90.77%, followed by dual therapy (8.99%). Among inpatients, monotherapy constituted 60.01%, dual therapy accounted for 37.33%. Among drugs ranked high in terms of DDDs, oral labetalol had a B/A ratio of 1, with a daily cost of 12.31 CNY; oral nifedipine had a B/A ratio > 1, with a daily cost of 1.03 CNY; and nicardipine for injection had a B/A ratio < 1, with a daily cost of 474.41 CNY.
conclusionThe use of antihypertensive drugs in patients with HDP is gradually aligning with guideline-recommended treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.